Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Feb 18

PMID 33597953

Citations 21

Authors

Tomohiro Koga

Kunihiro Ichinose

Atsushi Kawakami

George C Tsokos

Affiliations

Soon will be listed here.

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune cell abnormalities which lead to the production of autoantibodies and the deposition of immune complexes. Interleukin (IL)-17-producing cells play an important role in the pathogenesis of the disease, making them an attractive therapeutic target. Studies in lupus-prone mice and of cells from patients with SLE humans have shown that IL-17 represents a promising therapeutic target. Here we review molecular mechanisms involved in IL-17 production and Th17 cell differentiation and function and an update on the role of IL-17 in autoimmune diseases and the expected usefulness for targeting IL-17 therapeutically.

Citing Articles

Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review.

Blagov A, Orekhov N, Churov A, Starodubtseva I, Beloyartsev D, Kovyanova T Antib Ther. 2025; 8(1):47-55.

PMID: 39958566 PMC: 11826920. DOI: 10.1093/abt/tbae033.

Role of Interleukin-17 in Predicting Activity of Rheumatoid Arthritis and Systemic Lupus Erythematosus.

Samaan S, Taha S, Mahmoud F, Elsaadawy Y, Khalil S, Gamal D Clin Med Insights Arthritis Musculoskelet Disord. 2024; 17:11795441241276880.

PMID: 39351141 PMC: 11440548. DOI: 10.1177/11795441241276880.

Psoriasis and Lupus Erythematosus-Similarities and Differences between Two Autoimmune Diseases.

Fijalkowska A, Wojtania J, Wozniacka A, Robak E J Clin Med. 2024; 13(15).

PMID: 39124628 PMC: 11312967. DOI: 10.3390/jcm13154361.

Imbalance of Th17 cells, Treg cells and associated cytokines in patients with systemic lupus erythematosus: a meta-analysis.

Huang J, Li X, Zhu Q, Wang M, Xie Z, Zhao T Front Immunol. 2024; 15():1425847.

PMID: 39086480 PMC: 11288813. DOI: 10.3389/fimmu.2024.1425847.

Lymphocyte apoptosis and its association with the inflammatory markers and disease severity in juvenile-onset systemic lupus erythematosus patients.

Eissa E, Kandil R, Dorgham D, Ghorab R, Kholoussi N Pediatr Rheumatol Online J. 2024; 22(1):20.

PMID: 38243322 PMC: 10799351. DOI: 10.1186/s12969-024-00953-9.

References

Vincent F, Northcott M, Hoi A, Mackay F, Morand E . Clinical associations of serum interleukin-17 in systemic lupus erythematosus. Arthritis Res Ther. 2013; 15(4):R97. PMC: 3979031. DOI: 10.1186/ar4277. View

Schiffer L, Sinha J, Wang X, Huang W, Gersdorff G, Schiffer M . Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J Immunol. 2003; 171(1):489-97. DOI: 10.4049/jimmunol.171.1.489. View

Burkett P, Meyer Zu Horste G, Kuchroo V . Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J Clin Invest. 2015; 125(6):2211-9. PMC: 4497747. DOI: 10.1172/JCI78085. View

Waite J, Skokos D . Th17 response and inflammatory autoimmune diseases. Int J Inflam. 2012; 2012:819467. PMC: 3249891. DOI: 10.1155/2012/819467. View

Apostolidis S, Rauen T, Hedrich C, Tsokos G, Crispin J . Protein phosphatase 2A enables expression of interleukin 17 (IL-17) through chromatin remodeling. J Biol Chem. 2013; 288(37):26775-84. PMC: 3772223. DOI: 10.1074/jbc.M113.483743. View

Lopez P, Rodriguez-Carrio J, Caminal-Montero L, Mozo L, Suarez A . A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients. Sci Rep. 2016; 6:20651. PMC: 4742957. DOI: 10.1038/srep20651. View

Powell J, Delgoffe G . The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity. 2010; 33(3):301-11. PMC: 2962404. DOI: 10.1016/j.immuni.2010.09.002. View

Lai Z, Borsuk R, Shadakshari A, Yu J, Dawood M, Garcia R . Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol. 2013; 191(5):2236-46. PMC: 3777662. DOI: 10.4049/jimmunol.1301005. View

Sunahori K, Juang Y, Tsokos G . Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. J Immunol. 2009; 182(3):1500-8. PMC: 2676107. DOI: 10.4049/jimmunol.182.3.1500. View

10.

Moulton V, Tsokos G . T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest. 2015; 125(6):2220-7. PMC: 4497749. DOI: 10.1172/JCI78087. View

11.

Rullo O, Tsao B . Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis. 2012; 72 Suppl 2:ii56-61. PMC: 3780983. DOI: 10.1136/annrheumdis-2012-202351. View

12.

Otomo K, Koga T, Mizui M, Yoshida N, Kriegel C, Bickerton S . Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice. J Immunol. 2015; 195(12):5533-7. PMC: 4670795. DOI: 10.4049/jimmunol.1501603. View

13.

Griffiths C, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A . Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015; 386(9993):541-51. DOI: 10.1016/S0140-6736(15)60125-8. View

14.

Thumkeo D, Watanabe S, Narumiya S . Physiological roles of Rho and Rho effectors in mammals. Eur J Cell Biol. 2013; 92(10-11):303-15. DOI: 10.1016/j.ejcb.2013.09.002. View

15.

van Vollenhoven R, Hahn B, Tsokos G, Wagner C, Lipsky P, Touma Z . Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018; 392(10155):1330-1339. DOI: 10.1016/S0140-6736(18)32167-6. View

16.

Tsokos G . Systemic lupus erythematosus. N Engl J Med. 2011; 365(22):2110-21. DOI: 10.1056/NEJMra1100359. View

17.

McInnes I, Mease P, Kirkham B, Kavanaugh A, Ritchlin C, Rahman P . Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 386(9999):1137-46. DOI: 10.1016/S0140-6736(15)61134-5. View

18.

Pan W, Sharabi A, Ferretti A, Zhang Y, Burbano C, Yoshida N . PPP2R2D suppresses IL-2 production and Treg function. JCI Insight. 2020; 5(19). PMC: 7566706. DOI: 10.1172/jci.insight.138215. View

19.

Lee J, Katakai T, Hara T, Gonda H, Sugai M, Shimizu A . Roles of p-ERM and Rho-ROCK signaling in lymphocyte polarity and uropod formation. J Cell Biol. 2004; 167(2):327-37. PMC: 2172551. DOI: 10.1083/jcb.200403091. View

20.

Wong C, Lit L, Shan Tam L, Li E, Wong P, Kei Lam C . Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin Immunol. 2008; 127(3):385-93. DOI: 10.1016/j.clim.2008.01.019. View